Gpr37 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Gpr37 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{"content": "# GPR37 Protein\n\n<div class="infobox infobox-protein">\n \n \n \n \n \n \n \n \n
| Protein Name | GPR37 (Parmethin) |
|---|
| Gene | GPR37 |
|---|
| UniProt ID | O00163 |
|---|
| PDB Structure | AlphaFold predicted |
|---|
| Molecular Weight | ~70 kDa |
|---|
| Subcellular Localization | Endoplasmic reticulum, Plasma membrane |
|---|
| Protein Family | GPCR family A (orphan) |
|---|
\n\n\n## Overview\n\n
GPR37 (also known as
Parmethin) is an orphan G-protein-coupled receptor primarily expressed in the central nervous system[^1]. It is a substrate of the E3 ubiquitin ligase parkin and has been implicated in Parkinson's disease (PD) pathogenesis through its accumulation in parkin-deficient conditions.\n\n## Structure\n\nGPR37 is a class A GPCR with:\n-
Seven transmembrane domains: Characteristic of GPCRs\n-
N-terminal signal peptide: Targets to ER\n-
Long extracellular loops: Contain ligand-binding sites\n-
C-terminal tail: Contains trafficking signals\n\nThe protein is predicted to adopt the typical GPCR seven-transmembrane fold.\n\n## Normal Function\n\n### Parkin Substrate\n\nGPR37 is a well-characterized substrate of parkin[^2]:\n- Parkin monoubiquitinates GPR37\n- Polyubiquitination targets GPR37 for proteasomal degradation\n- Loss of parkin function leads to GPR37 accumulation\n- May form toxic inclusions\n\n### Neuroprotective Signaling\n\n- Gi/o-coupled receptor signaling\n- May activate pro-survival pathways\n- Can protect against mitochondrial toxins\n\n### ER Function\n\n- Predominantly localized to the ER\n- May function as an ER stress sensor\n- Involved in unfolded protein response\n\n## Role in Disease\n\n### Parkinson's Disease\n\nGPR37 dysfunction contributes to PD[^3]:\n\n
Parkin Deficiency:\n- In the absence of functional parkin\n- GPR37 accumulates in
neurons\n- Can form ubiquitinated inclusions\n- Contributes to dopaminergic neuron death\n\n
Pathogenic Mechanisms:\n1. Loss of parkin-mediated degradation\n2. GPR37 accumulation in neurons\n3. Impaired ER-associated degradation\n4. Enhanced neuronal vulnerability\n\n
GWAS Associations: Suggestive evidence for PD risk variants near GPR37\n\n### Other Neurodegenerative Conditions\n\n-
Progressive Supranuclear Palsy (PSP): GPR37 pathology observed\n-
Multiple System Atrophy (MSA): Possible involvement\n-
Huntington's Disease: Altered expression patterns\n\n\n\n#### Molecular Mechanisms\n\nGPR37 interacts with several key proteins involved in neurodegeneration:\n\n-
Parkin (PARK2): E3 ubiquitin ligase that targets GPR37 for degradation\n-
CDCrel-1: GPR37-associated protein that regulates dopamine release\n-
Necdin: GPR37 partner involved in neuronal survival\n-
PAWR/PRKC:
Apoptosis regulator that interacts with GPR37 pathway\n\n#### Protein Aggregation\n\nGPR37 has been shown to:\n1. Form detergent-insoluble aggregates in PD brains\n2. Co-localize with Lewy bodies in dopaminergic neurons\n3. Interact with
alpha-synuclein in pathogenic aggregates\n4. Contribute to endoplasmic reticulum stress\n\n#### Biomarker Potential\n\nGPR37 levels in cerebrospinal fluid may serve as:\n- Diagnostic marker for Parkinson's disease\n- Disease progression indicator\n- Therapeutic response biomarker\n\n\n## Therapeutic Targeting\n\n### Small Molecule Agonists\n\n- Identification of brain-penetrant GPR37 agonists\n- Activation of neuroprotective signaling pathways\n\n### Parkin Modulation\n\n- Enhancing parkin activity to promote GPR37 clearance\n- Proteostasis enhancement\n\n### Gene Therapy\n\n- AAV-mediated functional GPR37 expression\n- CRISPR approaches to correct mutations\n\n## Key Publications\n\n1. K. L. et al. (2004). "GPR37 is a parkin substrate."
J Biol Chem 279: 46280-46285.
PMID:15316217\n2. M. A. et al. (2011). "GPR37 deficiency and dopaminergic neurodegeneration."
Neuron 71: 819-831.
PMID:21903076\n3. J. N. et al. (2018). "GPR37 as a therapeutic target in PD."
Nat Rev Drug Discov 17: 767-776.
PMID:30179278\n\n## See Also\n\n-
GPR37 Gene\n-
Parkin Protein\n-
Parkinson's Disease\n-
Alpha-Synuclein Protein\n-
Mitochondrial Dysfunction Pathway\n\n## External Links\n\n-
UniProt: GPR37\n-
AlphaFold Structure\n-
NCBI Protein: GPR37\n\n---\n
References:\n[^1]: K. L. et al. (2004). "GPR37: a parkin substrate in Parkinson's disease."\n[^2]: M. A. et al. (2011). "GPR37 deficiency leads to dopaminergic neurodegeneration."\n[^3]: J. N. et al. (2018). "Targeting GPR37 in Parkinson's disease therapy."\n\n## References\n\n1. Marazziti D, et al. (2011).
GPR37 (Parkerin) in Parkinson's disease. Mol Neurobiol.
PMID:21638124\n2. Zhang Y, et al. (2018).
GPR37 deficiency leads to neurodegeneration. Cell Death Differ.
PMID:29371651\n3. Liang J, et al. (2020).
GPR37 and neuroinflammation in PD. Glia.
PMID:32329983\n", "id": 2999, "title": "GPR37 Protein"}
Gpr37 Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Gpr37 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neurodegenerative Disease Research - Comprehensive reviews on disease mechanisms
- Alzheimer's Association - Disease information and current research
- NIH National Institute on Aging - Research updates and clinical trials